Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study
Key facts
- Who runs it
- Sichuan Provincial People's Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 11 Nov 2025
- Expected to end
- 11 Nov 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Sulbactam-Durlobactam
- Record updated
- 22 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Age ≥18 years
- Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:; patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or; transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy
- Treatment initiation time can be clearly determined
- Availability of clinical outcome data
Who cannot take part
- Colonization without evidence of active infection
- Missing key clinical data
- Inability to determine treatment initiation time
- Pregnancy or lactation
- Patients considered unsuitable by investigators
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.
Read full original descriptionShow less
The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.
To reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.
The 2 groups in the trial
- Sulbactam-Durlobactam Group
Patients receiving sulbactam-durlobactam within 48 hours after treatment initiation.
Treatment: Sulbactam-Durlobactam
- Non-Sulbactam-Durlobactam Group
Patients receiving alternative anti-CRAB regimens during the same period without sulbactam-durlobactam.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- This is a Single-center Real-world Observational Cohort Study of Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter Baumannii Infections: Effectiveness, Safety, and Exposure-Response Analysis
- Criteria questions
- Built from NCT07601711, who can take part
- Record updated
- 22 May 2026